Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRAUX, Pierre-Louis
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorDRUTEL, Guillaume
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorREVEST, Jean-Michel
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorVALLEE, Monique
dc.date.accessioned2022-03-31T14:36:26Z
dc.date.available2022-03-31T14:36:26Z
dc.date.issued2022-02
dc.identifier.issn1365-2826en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136582
dc.description.abstractEnPregnenolone is a steroid with specific characteristics, being the first steroid to be synthesised from cholesterol at all sites of steroidogenesis, including the brain. For many years, pregnenolone was defined as an inactive precursor of all steroids because no specific target had been discovered. However, over the last decade, it has become a steroid of interest because it has been recognised as being a biomarker for brain-related disorders through the development of metabolomic approaches and advanced analytical methods. In addition, physiological roles for pregnenolone emerged when specific targets were discovered. In this review, we highlight the discovery of the selective interaction of pregnenolone with the type-1 cannabinoid receptor (CB1R). After describing the specific characteristic of CB1Rs, we discuss the newly discovered mechanisms of their regulation by pregnenolone. In particular, we describe the action of pregnenolone as a negative allosteric modulator and a specific signalling inhibitor of the CB1R. These particular characteristics of pregnenolone provide a great strategic opportunity for therapeutic development in CB1-related disorders. Finally, we outline new perspectives using innovative genetic tools for the discovery of original regulatory mechanisms of pregnenolone on CB1-related functions.
dc.language.isoENen_US
dc.subject.enAllosteric regulation
dc.subject.enBiased signalling
dc.subject.enGPCR
dc.subject.enNeurosteroids
dc.subject.enPregnenolone
dc.subject.enType-1 cannabinoid receptor (CB1R)
dc.title.enNew perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function
dc.title.alternativeJ Neuroendocrinolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/jne.13034en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed34486765en_US
bordeaux.journalJournal of Neuroendocrinologyen_US
bordeaux.volume34en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDConseil Régional Aquitaineen_US
bordeaux.identifier.funderIDUniversité de Bordeauxen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Neuroendocrinology&rft.date=2022-02&rft.volume=34&rft.issue=2&rft.eissn=1365-2826&rft.issn=1365-2826&rft.au=RAUX,%20Pierre-Louis&DRUTEL,%20Guillaume&REVEST,%20Jean-Michel&VALLEE,%20Monique&rft.genre=article


Archivos en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem